Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine for Steroid Resistant Chronic GVHD
NCT00004194Phase 2Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in graft-versus-host disease (GVHD), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose, Toxicity and 1 more. Status: unknown.
02
Drugs
fludarabine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00004194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004194.